Effect of peritoneal dialysis solution type on serum lipid levels in end-stage renal disease

Renal Failure

Volumn 29, Issue 3, 2007, Pages 309-313

  Kanbay, M ^a   Bavbek, N ^a,c   Delibasi, T ^b   Koca, C ^a   Kaya, A ^a   Altay, M ^b   Akcay, A ^a   Duranay, M ^a   Yigitoglu, R ^a  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^b Training Hospital   (Turkey)

^c Department of Biochemistry ^*  (Turkey)

Author keywords

Continuous ambulatory peritoneal dialysis; High density lipoprotein; Lipoprotein (a); Low density lipoprotein; Total cholesterol; Triglyceride

Indexed keywords

AMINO ACID; CHOLESTEROL; DIALYSIS FLUID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICODEXTRIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; KIDNEY FAILURE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIALYSIS SOLUTIONS; DYSLIPIDEMIAS; FEMALE; GLUCANS; GLUCOSE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 34248596020     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220601166545     Document Type: Article

References (30)

1. Gokal R. Taking peritoneal dialysis beyond the year 2000. Perit Dial Int. 1999;19:35-43.
2. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipoprotein (a) in patients on maintenance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1993;8:609-613.
3. Brunner FP, Fassbinder W, Broyer M, et al. Survival on renal replacement therapy: data from the EDTA Registry. Nephrol Dial Transplant. 1988;3:109-122.
4. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extend of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:352-362.
5. Avram MM, Bonomini LV, Sreedhara R, Mittman N. Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis. 1996;28:910-917.
6. Bagdade JD, Porte D Jr, Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med. 1968;279:181-185.
7. Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. Am J Med. 1998;105:48-57.
8. Steele J, Billington T, Janus E, Moran J. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Atherosclerosis. 1989;79:47-50.
9. Delarue J, Maingourd C, Couet C, Vidal S, Bagros P, Lamisse F. Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Perit Dial Int. 1998;18:505-511.
10. Pers E. Icodextrin plus glucose combinations for use in CAPD. Perit Dial Int. 1997;17:68-69.
11. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int. 1994;46:496-503.
12. Oreopoulos DG, Crassweller P, Katirtzoglu A, et al. Amino acids as an osmotic agent (instead of glucose) in continuous ambulatory peritoneal dialysis. In: Legrain M, ed. Proceedings of an International Symposium. Amsterdam: Excerpta Medica; 1979: 335-340.
13. Lindholm B, Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand. 1986;220:143-151.
14. Lindholm B, Bergstrouml MJ. Nutritional aspects of CAPD. In: Gokal R, ed. Continuous ambulatory peritoneal dialysis. London: Churchill- Livingstone, 1986:228-265.
15. Young EA, Drummond A, Cool DA, et al. The effect of insulin on the metabolism of parenteral maltose in man. J Clin Endocrinol Metab. 1980;50:764-772.
16. Posthuma N, Ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA. Peritoneal defense using icodextrin or glucose for daytime dwell in CAPD patients. Perit Dial Int. 1999;19:334-342.
17. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int. 2001;21:275-281.
18. Young GA, Dibble JB, Hobson SM, et al. The use of an amino-acid-based CAPD fluid over 12 weeks. Nephrol Dial Transplant. 1989;4:285-292.
19. Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F. CAPD with an amino acid dialysis solution: a long term, cross-over study. Kidney Int. 1989;35:1189-1194.
20. Pedersen FB. Alternate use of amino acid and glucose solutions in CAPD. A review. Contrib Nephrol. 1991;89:147-154.
21. Misra M, Reaveley DA, Ashworth J, Muller B, Seed M, Brown EA. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 1997;17:279-286.
22. Dibble JB, Young GA, Hobson SM, Brownjohn AM. Amino-acid-based continuous ambulatory peritoneal dialysis (CAPD) fluid over twelve weeks: effects on carbohydrate and lipid metabolism. Perit Dial Int. 1990;10:71-77.
23. Oren A, Wu G, Anderson GH, et al. Effective use of amino acid dialysate over four weeks in CAPD patients. Trans Am Soc Artif Intern Organs. 1983;29:604-610.
24. Dombros NV, Prutis K, Tong M, et al. Six-month overnight intraperitoneal amino-acid infusion in continuous ambulatory peritoneal dialysis (CAPD) patients - no effect on nutritional status. Perit Dial Int. 1990;10:79-84.
25. Renzo S, Beatrice D, Guiseppe L. CAPD in diabetics: use of amino acids. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in CAPD. Toronto: Peritoneal Dialysis Bulletin; 1990(6):53-55.
26. Arfeen S, Goodship TH, Kirkwood A, Ward MK. The nutritional/metabolic and hormonal effects of 8 weeks of continuous ambulatory peritoneal dialysis with a 1% amino acid solution. Clin Nephrol. 1990;33:192-199.
27. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 1986;62:249-257.
28. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein(a) concentrations in uremic patients treated with CAPD. Clin Nephrol. 1992;38:271-276.
29. Kimak E, Solski J. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, CAPD and post-transplant patients. Ren Fail. 2002;24:187-195.
30. Heimburger O, Stenvinkel P, Berglund L, Tranoeus A, Lindholm B. Increased plasma lipoprotein(a) in CAPD is related to peritoneal transport of proteins and glucose. Nephron. 1996;72:135-144.